Jonathan Villena‐Vargas

2.9k total citations · 2 hit papers
39 papers, 2.1k citations indexed

About

Jonathan Villena‐Vargas is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jonathan Villena‐Vargas has authored 39 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 9 papers in Surgery. Recurrent topics in Jonathan Villena‐Vargas's work include Lung Cancer Diagnosis and Treatment (15 papers), Lung Cancer Treatments and Mutations (11 papers) and CAR-T cell therapy research (6 papers). Jonathan Villena‐Vargas is often cited by papers focused on Lung Cancer Diagnosis and Treatment (15 papers), Lung Cancer Treatments and Mutations (11 papers) and CAR-T cell therapy research (6 papers). Jonathan Villena‐Vargas collaborates with scholars based in United States, Japan and Egypt. Jonathan Villena‐Vargas's co-authors include Prasad S. Adusumilli, David R. Jones, Michel Sadelain, Leonid Cherkassky, Aurore Morello, Yang Feng, Dimiter S. Dimitrov, Andreas R. de Biasi, Elliot L. Servais and Christos Colovos and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Jonathan Villena‐Vargas

35 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

2016 803 citations Leonid Cherkassky, Aurore Morello et al. profile →
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

2014 434 citations Prasad S. Adusumilli, Leonid Cherkassky et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Villena‐Vargas United States	14	1.6k	622	520	446	394	39	2.1k
Leonid Cherkassky United States	12	1.6k 1.0×	762 1.2×	234 0.5×	507 1.1×	588 1.5×	22	2.1k
Özlem Anak Switzerland	12	1.6k 1.0×	341 0.5×	273 0.5×	357 0.8×	521 1.3×	25	2.0k
Mio Kitano United States	11	1.9k 1.2×	797 1.3×	76 0.1×	646 1.4×	599 1.5×	21	2.4k
Anthony R. Mato United States	24	1.9k 1.2×	619 1.0×	242 0.5×	440 1.0×	632 1.6×	85	2.8k
Saad S. Kenderian United States	25	2.1k 1.3×	790 1.3×	98 0.2×	537 1.2×	737 1.9×	149	2.9k
Andras Heczey United States	19	1.5k 0.9×	898 1.4×	82 0.2×	322 0.7×	527 1.3×	49	2.1k
Qunrui Ye United States	15	1.4k 0.9×	1.0k 1.6×	68 0.1×	303 0.7×	445 1.1×	17	2.0k
Yukimi Sakoda Japan	17	1.2k 0.8×	898 1.4×	81 0.2×	389 0.9×	361 0.9×	27	1.7k
Elise A. Chong United States	16	2.1k 1.3×	638 1.0×	71 0.1×	473 1.1×	509 1.3×	110	2.5k
Bianca Altvater Germany	24	993 0.6×	736 1.2×	249 0.5×	183 0.4×	355 0.9×	44	1.4k

Countries citing papers authored by Jonathan Villena‐Vargas

Since Specialization

Citations

This map shows the geographic impact of Jonathan Villena‐Vargas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Villena‐Vargas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Villena‐Vargas more than expected).

Fields of papers citing papers by Jonathan Villena‐Vargas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Villena‐Vargas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Villena‐Vargas. The network helps show where Jonathan Villena‐Vargas may publish in the future.

Co-authorship network of co-authors of Jonathan Villena‐Vargas

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Villena‐Vargas. A scholar is included among the top collaborators of Jonathan Villena‐Vargas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Villena‐Vargas. Jonathan Villena‐Vargas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

An, Anjile, et al.. (2025). Disparities in adherence to guideline-concordant care and receipt of immunotherapy for Non-Small cell lung cancer in the United States. Lung Cancer. 206. 108661–108661.

Ali, Muhammad, et al.. (2025). Robotic One Anaesthetic Marking And Resection ( ROMAR ): A Novel Approach for Thoracoscopic Sublobar Resection of Peripheral Pulmonary Lesions. Respirology.

Ghaly, Galal, Michelle Demetres, Abdelrahman Mohamed, et al.. (2024). Survival difference among adult and pediatric mediastinal yolk sac tumors cases: A meta-analysis of case reports. European Journal of Surgical Oncology. 50(3). 108019–108019. 2 indexed citations

Nasar, Abu, Jonathan Villena‐Vargas, S. Harrison, et al.. (2024). Does High Standard Uptake Value on Positron Emission Tomography Preclude Sublobar Resection in Stage IA Non-Small Cell Lung Cancer ≤2 cm?. The Annals of Thoracic Surgery. 119(5). 1092–1098.

Rahouma, Mohamed, Jonathan Villena‐Vargas, S. Harrison, et al.. (2024). A robotic-assisted thymectomy is equivalent to a transsternal resection in large thymomas. Journal of Thoracic Disease. 16(10). 6752–6759. 1 indexed citations

Nasar, Abu, Jonathan Villena‐Vargas, S. Harrison, et al.. (2024). Wedge resection, segmentectomy, and lobectomy: oncologic outcomes based on extent of surgical resection for ≤2 cm stage IA non-small cell lung cancer. Journal of Thoracic Disease. 16(3). 1875–1884. 2 indexed citations

Nasar, Abu, Jonathan Villena‐Vargas, Oliver S. Chow, et al.. (2023). Should sampling of three N2 stations be a quality metric for curative resection of stage I lung cancer?. Journal of Thoracic and Cardiovascular Surgery. 168(5). 1337–1345.e5. 4 indexed citations

Lee, Benjamin, Abu Nasar, Jonathan Villena‐Vargas, et al.. (2022). Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non–small cell lung cancer: Results from a randomized trial. Journal of Thoracic and Cardiovascular Surgery. 165(1). 327–334.e2. 11 indexed citations

Altorki, Nasser K., Abu Nasar, C Spinelli, et al.. (2022). Ten-Year Survival and Recurrence Patterns After Three-Field Lymph Node Dissection for Squamous Cell and Adenocarcinoma of the Esophagus. Annals of Surgery. 278(1). e43–e50. 8 indexed citations

10.

Villena‐Vargas, Jonathan, Abu Nasar, Francesca Voza, et al.. (2022). Safety of lung cancer surgery during COVID-19 in a pandemic epicenter. Journal of Thoracic and Cardiovascular Surgery. 164(2). 378–385. 5 indexed citations

11.

Gambardella, Ivancarmine, Raimondo Ascione, Dominic P. D’Agostino, et al.. (2021). Systematic Review ‐ Neuroprotection of ketosis in acute injury of the mammalian central nervous system: A meta‐analysis. Journal of Neurochemistry. 158(2). 105–118. 11 indexed citations

12.

Hocine, Hocine R., Maxim A. Moroz, Srijita Banerjee, et al.. (2021). Imaging CAR T-cell kinetics in solid tumors: Translational implications. Molecular Therapy — Oncolytics. 22. 355–367. 30 indexed citations

13.

Saxena, Ashish, Jeffrey L. Port, Benjamin E. Lee, et al.. (2021). Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report. Clinical Lung Cancer. 23(3). e238–e242. 16 indexed citations

14.

Kamel, Mohamed, Jonathan Villena‐Vargas, Mohamed Rahouma, et al.. (2019). National trends and perioperative outcomes of robotic resection of thymic tumours in the United States: a propensity matching comparison with open and video-assisted thoracoscopic approaches†. European Journal of Cardio-Thoracic Surgery. 56(4). 762–769. 21 indexed citations

15.

Villena‐Vargas, Jonathan, et al.. (2017). MA13.07 Tumor-Targeted Radiation Promotes Abscopal Efficacy of Regionally Administered CAR T Cells: A Rationale for Clinical Trial. Journal of Thoracic Oncology. 12(1). S419–S419. 3 indexed citations

16.

Kadota, Kyuichi, Daniel Buitrago, Ming-Ching Lee, et al.. (2015). Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma. Lung Cancer. 89(3). 329–336. 14 indexed citations

17.

Cherkassky, Leonid, Jonathan Villena‐Vargas, Aurore Morello, et al.. (2014). Mesothelin-targeted T Cells Gene-Engineered with 4-1BB Costimulation Overcome Tumor-Mediated Immunoinhibition and Eradicate Established Solid Tumors. Journal of the American College of Surgeons. 219(3). S134–S134. 1 indexed citations

18.

Kadota, Kyuichi, Jonathan Villena‐Vargas, Akihiko Yoshizawa, et al.. (2014). Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease. The American Journal of Surgical Pathology. 38(4). 448–460. 183 indexed citations

19.

Kachala, Stefan S., Adam J. Bograd, Jonathan Villena‐Vargas, et al.. (2013). Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma. Clinical Cancer Research. 20(4). 1020–1028. 132 indexed citations

20.

Villena‐Vargas, Jonathan & Prasad S. Adusumilli. (2012). Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.. PubMed. 1(4). 466–71. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact